Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

10.1038/nrclinonc.2012.59

10.1038/nrc1187

10.1093/annonc/mdr533

10.1586/era.12.81

10.1038/sj.bjc.6605298

10.1016/S1470-2045(09)70240-2

Tamaskar I., Dhillon J., Pili R., Resistance to angiogenesis inhibitors in renal cell carcinoma. Clin. Adv. Hematol. Oncol. 9, 101–110 (2011).

10.1016/S0065-230X(06)96007-2

10.1038/nrc3001

10.1038/nrd1635

10.1038/nrclinonc.2011.21

Man S., Bocci G., Francia G., Green S. K., Jothy S., Hanahan D., Bohlen P., Hicklin D. J., Bergers G., Kerbel R. S., Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62, 2731–2735 (2002).

10.1158/0008-5472.CAN-05-4411

10.1136/gutjnl-2011-301585

10.1593/neo.91872

10.1158/0008-5472.CAN-08-0041

10.1158/1078-0432.CCR-09-0931

10.1158/0008-5472.CAN-12-4183

10.1158/1535-7163.MCT-09-0960

10.1007/BF01753659

Naito S., von Eschenbach A. C., Giavazzi R., Fidler I. J., Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 46, 4109–4115 (1986).

10.1016/j.hoc.2011.05.001

10.1111/j.1442-2042.2012.03065.x

10.1159/000338057

10.1002/cncr.11436

10.1158/1078-0432.CCR-11-0078

10.1007/BF00874445

10.1593/neo.101334

10.1158/0008-5472.CAN-09-1947

10.1158/1078-0432.CCR-11-1667

10.1210/jc.2013-1364

10.1200/JCO.2011.35.7376

Turner D. C., Tillmanns T. D., Harstead K. E., Throm S. L., Stewart C. F., Combination metronomic oral topotecan and pazopanib: A pharmacokinetic study in patients with gynecological cancer. Anticancer Res. 33, 3823–3829 (2013).

10.1007/s10637-012-9921-8

10.1158/1078-0432.CCR-14-2810

S. M. Keefe M. Hennessy O. Gunnarsson R. Mamtani D. Vaughn J. Hoffman-Censits K. Nathanson Priti Lal P. Lal D. Pryma S. Eliasof E. Garmey R. B. Cohen N. B. Haas Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC): Results from the planned interim analysis. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research San Diego CA 5 to 9 April 2014.

10.1016/S1470-2045(09)70383-3

10.1056/NEJMoa032691

10.1016/S0140-6736(14)62004-3

10.1007/s00280-013-2176-z

10.1016/j.ccr.2012.03.002

Zhong X., Li X., Wang G., Zhu Y., Hu G., Zhao J., Neace C., Ding H., Reed E., Li Q. Q., Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int. J. Oncol. 25, 445–451 (2004).

10.1200/JCO.2011.38.5492

10.2147/OTT.S68386

10.1200/JCO.2012.45.1930

10.1097/JTO.0000000000000227

10.1007/BF02617972

10.1038/nm0895-822

10.1016/S0959-8049(00)00302-6

Cruz-Muñoz W., Di Desidero T., Man S., Xu P., Jaramillo M. L., Hashimoto K., Collins C., Banville M., O’Connor-McCourt M. D., Kerbel R. S., Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis 17, 661–673 (2014).

10.1002/ijc.22572